A phase 2 GALAXY study presented at the ESMO Gastrointestinal Cancers Congress 2026 suggests that circulating tumor DNA (ctDNA) testing after surgery could help identify which patients with colorectal cancer that has spread to the liver are most likely to benefit from adjuvant chemotherapy. Researchers…
Atlanta Gastroenterology Associates has agreed to pay $4.75 million to settle allegations that it violated the False Claims Act by…
The U.S. healthcare system is approaching a tipping point, driven by three converging threats: rising care costs, a growing chronic…
In a bid to close persistent colorectal cancer (CRC) screening gaps, Guardant Health has launched a community grant program offering…
The 2025 Identity Theft Resource Center report confirms what many physician-owners are feeling: cyberattacks are no longer random — they’re…
DDW 2026
Several studies presented at DDW 2026 highlighted emerging approaches that could reshape…
A structured triage system for interventional GI referrals changed the originally requested…
Headlines in GI
Two gastroenterology organizations have disclosed phishing-related data breaches that exposed sensitive patient…
Thought Leadership
Why Pathways Need Orchestration Before They Can Scale By Dr. Charles Accurso…
This GI & Hepatology News Perspectives article provides practical guidance from experienced…
In the latest edition of The Scope Forward Show, I’m joined by Matt…
ARTIFICIAL INTELLIGENCE (AI)
A new meta-analysis of 14 studies found that deep learning (AI) systems can detect early esophageal squamous cell carcinoma (ESCC)…
Tech & Innovation
Today’s endoscopy suite is poised for a major transformation, driven by rapid advances in imaging technology, artificial intelligence, and device innovation. Speaking at the 2026 Expert…
Exponential Tech
Today’s endoscopy suite is poised for a major transformation, driven by rapid…